Literature DB >> 14521555

Erythema dyschromicum perstans in prepubertal children.

Nanette B Silverberg1, Joshua Herz, Annette Wagner, Amy S Paller.   

Abstract

Erythema dyschromicum perstans (EDP) is a rare disorder of pigmentation that is most common in Hispanic patients. In adults, EDP has a slow onset and is unlikely to resolve spontaneously. The etiology and clinical course in children is poorly defined. Physical examinations, chart reviews, and telephone interviews were performed for eight pediatric patients with EDP who were followed at Children's Memorial Hospital in Chicago between 1990 and 1998. All the patients available for long-term follow-up (five of the eight) experienced complete clearance without recurrence in an average of 2.5 years. In all of our patients, the onset was noted from July to December. The administration of aminopenicillins was coincident with the development of EDP in two of the patients. Review of the English-language literature reveals that 25 prepubertal children have previously been reported. Including our patients, 69% of prepubertal children with EDP experienced resolution. We concluded that the clinical course of childhood (prepubertal) EDP differs from that of adult EDP, and it is more likely to resolve within 2-3 years.

Entities:  

Mesh:

Year:  2003        PMID: 14521555     DOI: 10.1046/j.1525-1470.2003.20505.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  3 in total

1.  Ashy dermatosis in an 8-year-old Indian child.

Authors:  Chitralekha Keisham; Rashmi Sarkar; V K Garg; Shikha Chugh
Journal:  Indian Dermatol Online J       Date:  2013-01

2.  Erythema dyschromicum perstans showing resolution in an adult.

Authors:  Nina K Antonov; Irwin Braverman; Antonio Subtil; Charles L Halasz
Journal:  JAAD Case Rep       Date:  2015-06-10

3.  Erythema Dyschromicum Perstans in an 8-Year-Old Indian Child.

Authors:  Alexander K C Leung; Joseph M Lam
Journal:  Case Rep Dermatol Med       Date:  2018-07-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.